AndreHGoyMD

PubMed

• 67 citations
  Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma.
  Sattva S Neelapu, Caron A Jacobson, Armin Ghobadi, David B Miklos, Lazaros J Lekakis
  Blood. 2023-05-11
• 807 citations
  Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
  Wyndham H. Wilson, Ryan M. Young, Roland Schmitz, Yandan Yang, Stefania Pittaluga
  Nature Medicine. 2015-07-20
• 814 citations
  PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
  Ajay K. Gopal, Brad S. Kahl, Sven de Vos, Nina D. Wagner-Johnston, Stephen J. Schuster
  The New England Journal of Medicine. 2014-03-12

Journal Articles

• Ibrutinib for the Treatment of relapsed/refractory Mantle Cell Lymphoma: Extended 3.5-year Follow-up from a Pooled Analysis  
  Brad Kahl, Andre Goy, Haematologica
• Venetoclax plus R- or G-CHOP in Non-Hodgkin Lymphoma: Results from the CAVALLI Phase 1b Trial  
  Andrew D Zelenetz, Andre Goy, Mehrdad Mobasher, Carla Casulo, Blood
• Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration  
  Cheah CY, Bröckelmann PJ, Chihara D, Moskowitz AJ, Engert A, Jerkeman M, El-Galaly TC, Augustson B, Vose J, Bartlett NL, Villa D, Connors JM, Feldman T, Pinnix CC, Mil..., Am J Hematol., 1/1/2016
• Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy  
  Abramson JS, Feldman T, Kroll-Desrosiers AR, Muffly LS, Winer E, Flowers CR, Lansigan F, Nabhan C, Nastoupil LJ, Nath R, Goy A, Castillo JJ, Jagadeesh D, Woda B, Rosen..., Ann Oncol., 1/1/2014
• A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: correlation between clinical responses and...  
  Casulo C, Vose JM, Ho WY, Kahl B, Brunvand M, Goy A, Kasamon Y, Cheson B, Friedberg JW, Clin Immunol., 1/1/2014
• Mantle cell lymphoma: continuously improving the odds!  
  Andre Goy, Expert Opinion on Orphan Drugs., 1/1/2013
• Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell ...  
  Romaguera JE, Fayad LE, Feng L, Hartig K, Weaver P, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Cabanillas F, Kantarjian H, Kwak L..., Br J Haematol., 1/1/2010
• Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 3 PINNACLE study  
  Goy A, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, Epner E, Krishnan A, Leonard JP, Lonial S, Nasta S, O'Connor OA, Shi H, Boral AL, Fisher RI, Ann Oncol., 1/1/2009
• Mantle cell lymphoma: evolving novel options  
  Goy A, Current Oncology Rep, 1/1/2007
• Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relap...  
  Pro B, Fayad L, McLAughlin P, Romaguera J, Hagemeister R, Rodriguez MA, Goy A, Younes A, Leukemia Lymphoma, 1/1/2006
• Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with thenovel proteasome inhibitor bortezomib: a possible surrogate marker of response?  
  Gerecitano J, Goy A, Wright J, MacGregor-Cortelli B, Neylon E, Gonen M, Esseltine D, Boral A, Schenkein D, Busam K, Teruya-Feldstein J, Sachs D, O’Connor OA., Br J Haematol, 1/1/2006
• Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma  
  Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, Epner E, Krishnan A, Leonard JP, Lonial S, Stadtmauer EA, O'Connor OA, Shi H, Boral AL, Goy A, Journal of Clinical Oncology, 1/1/2006
• Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma  
  Younes A, Fayad L, Romaguera J, Pro B, Goy A, Wang M, European Journal Cancer., 1/1/2006
• Phase II Study of Proteasome Inhibitor Bortezomib (VELCADETM) in Patients with Relapsed or Refractory Indolent or Aggressive Lymphomas  
  Andre Goy, Anas Younes, Peter McLaughlin, Barbara Pro, Jorge E. Romaguera, Frederick Hagemeister, Luis Fayad, Nam H Dang, Felipe Samaniego, Michael Wang, Kristine Brog..., Journal of Clinical Oncology, 1/1/2005
• Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of condit...  
  Anderlini P, Saliba R, Acholonu S, Okoroji GJ, Donato M, Giralt S, Andersson B, Ueno NT, Khouri I, De Lima M, Hosing C, Cohen A, Ippoliti C, Romaguera J, Rodriguez MA,..., Bone Marrow Transplant, 1/1/2005
• Signal transducer and activator of transcription-3 activation contributes to high tissue inhibitor of metalloproteinase-1 expression in anaplastic  
  Lai R, Rassidakis GZ, Medeiros LJ, Ramdas L, Goy A, Cutler C, Fujio Y, Kunisada K, Amin HM, Gilles F., Am J Pathol, 1/1/2004
• Establishment and characterization of a new mantle cell lymphoma cell line M-1  
  Goy A, Remache YK, Gu J, Stewart J, Hayes KJ, Gold D, Jiang Y, Barkoh BA, Katz R, Cabanillas F, Gilles F., Leukemia Lymphoma, 1/1/2004
• Suppressor of cytokine signaling 3 expressions in anaplastic large cell lymphoma  
  Cho-Vega JH, Rassidakis GZ, Amin HM, Tsioli P, Spurger K, Remache YK, Vega F, Goy A, Gilles F, Medeiros J., Leukemia, 1/1/2004
• Radiolabeled antibody therapy in non-Hodgkins lymphoma: radiation protection, isotope comparisons and quality of life issues  
  Silverman DH, Delpassand ES, Torabi F, Goy A, McLaughlin P, Murray JL., Cancer Treat Rev., 1/1/2004
• Prognostic significance of MUC-1 expression in systemic anaplastic large cell lymphoma  
  Rassidakis GZ, Goy A, Medeiros LJ, Jiang Y, Thomaides A, Remache Y, Cabanillas F, Sarris AH, Gilles F., Clinical Cancer Research, 1/1/2003
• Pentostatin in T-non-Hodgkin’s lymphomas: efficacy and effect on CD26+ T lymphocytes  
  Dang, NH, Hagemeister, FB, Duvic M, Romaguera J, Younes A, Jones D, Samuels B, Fayad L, Pro B, Samaniego F, Sarris A, Goy A, McLaughlin P, Tong AT, Walker PL, Tiongson..., Oncology Rep, 1/1/2003
• T(14;18)-positive cells in peripheral blood (PB) and bone marrow (BM) of patients with follicular lymphoma (Fl) treated with Fnd+Rituxan  
  Jiang Y, Thomaides A, Rassidakis G, Sneed T, McLaughlin P, Medeiros LJ, Sarris A, Cabanillas F and Goy A., Ann Oncology, 1/1/2002
• Muc-1 is frequently expressed in systemic and primary cutaneous anaplastic large cell lymphoma (ALCL) but rarely in other peripheral T-cell lymphoma (PTCL)  
  Rassidakis G.Z, Jones D, Medeiros LJ, Jiang Y, Thomaides A, Sarris AH, Cabanillas F, Gilles F, and Goy A, Ann Oncology, 1/1/2002
• Irinotecan in relapsed or refractory non-Hodgkin's lymphomas Indications of activity in a phase II trial  
  Sarris AH, Phan A, Goy A, Romaguera J, Hagemeister F, Rodriguez MA, McLaughlin P, Pro B, Medeiros LJ, Samuels B, Mesina O, Bleyer AW, Cabanillas F., Oncology (Hunyingt), 1/1/2002
• Establishment of a human cell line (SKI-DLCL-1) with a t(1;14)(q21;q32) translocation from the ascites of a patient with diffuse large cell lymphoma  
  Goy A, Gilles F, Remache Y, Filippa D, Portlock CS, Jhanwar SC, Zelenetz AD, Leukemia Lymphoma, 1/1/2001
• Join now to see all

Books/Book Chapters

• Series: Emerging Cancer Therapeutics- Lymphomas 
  Goy, A.New York, NY2012
• Bortezomib in the Treatment of Multiple Myeloma 
  Ghobrial, Irene M.; Richardson, Paul GEdition 1st,2011

Abstracts/Posters

• Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymph...
  Andre Goy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Evomela¬ Significantly Increases the Risk of Engraftment Syndrome in Patients with Multiple Myeloma Treated with Autologous Stem Cell Transplantation
  Andre Goy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium
  Andre Goy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymph...
  Andre Goy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Engraftment Syndrome in the Setting of Autologous Stem Cell Transplantation for Multiple Myeloma-a Single Institution Review of over 600 Patients
  Andre Goy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Phase 2 Results of the iR2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell_like (Non-GCB) Diffus...
  Andre Goy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Toxicities and Outcomes of Acalabrutinib-Treated Patients with Chronic Lymphocytic Leukemia: A Retrospective Analysis of Real World Patients
  Andre Goy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase...
  Andre Goy, 61st Annual American Society of Hematology Meeting, 61st Annual American Society of Hematology Meeting - Orlando, FL, 12/7/2019
• Patterns of Treatment for Newly Diagnosed and Relapsed/Refractory Peripheral T-Cell Lymphoma in the Community Setting
  Tatyana Feldman, Michael McGuire, Claudio Faria, Andre Goy, Charles Michael Farber, Kelly Choi, Jacqueline Connors, Dhakshila Paramanathan, Eric Schultz, Stuart L. Gol..., ASH Annual Meeting Abstracts, 1/1/2015
• Clinical Impact of Internet-Based Tools to Help Guide Therapeutic Decisions for Mantle Cell Lymphoma (MCL)
  Kristen M Rosenthal, Christopher R. Flowers, Andre Goy, John P. Leonard, Julie M. Vose, Erik D. Brady, Jim Mortimer, Kevin L Obholz, James O. Armitage., ASH Annual Meeting Abstracts, 1/1/2015
• Allogeneic T-Cells Expressing an Anti-CD19 Chimeric Antigen Receptor Cause Remissions of B-Cell Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation w...
  Jennifer N Brudno, Robert Somerville, Victoria Shi, Jeremy J. Rose, David C. Halverson, Daniel H. Fowler, Dennis D. Hickstein, Juan C. Gea-Banacloche, Steven Z. Pavlet..., ASH Annual Meeting Abstracts, 1/1/2015
• Favorable Outcomes in CLL Pts with Alternate Kinase Inhibitors Following Ibrutinib or Idelalisib Discontinuation: Results from a Large Multi-Center Study
  Anthony Mato, Chadi Nabhan, Paul M. Barr, Chaitra S. Ujjani, Brian T. Hill, Nicole Lamanna, Alan P Skarbnik, Christina Howlett, PharmD, Jeffrey J Pu, Alison R. Sehgal,..., ASH Annual Meeting Abstracts, 1/1/2015
• BET Inhibitor CPI-0610 Is Well Tolerated and Induces Responses in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma: Preliminary Analysis of an Ongoing Phase 1 Study
  Jeremy S. Abramson, Kristie A. Blum, Ian W. Flinn, Martin Gutierrez, Andre Goy, Michael Maris, Michael Cooper, Michael O'Meara, Darrell Borger, Jennifer Mertz, Robert ..., ASH Annual Meeting Abstracts, 1/1/2015
• Phase IIa Study of Single-Agent MOR208 in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
  Wojciech Jurczak, Pier Luigi Zinzani, Gianluca Gaidano, Andre Goy, Mariano Provencio, Zsolt Nagy, Tadeusz Robak, Kami J. Maddocks, Christian Buske, Roman Pawel Korolki..., ASH Annual Meeting Abstracts, 1/1/2015
• Impact of High Risk Prognostic Parameters and Addition of Ibrutinib to Bendamustine/Rituximab (BR) on Outcomes for Patients with Relapsed Chronic Lymphocytic Leukemia/...
  Asher Chanan-Khan, Paula Cramer, Graeme Fraser, Rodrigo Santucci Silva, Sebastian Grosicki, Aleksander Pristupa, Marie Sarah Dilhuydy, Andre Goy, Anthony R. Mato, Raje..., ASH Annual Meeting Abstracts, 1/1/2015
• Idelalisib Monotherapy and Durable Responses in Patients with Relapsed or Refractory Small Lymphocytic Lymphoma (SLL)
  Ajay K Gopal, Andrew John Davies, Ian W. Flinn, Paolo Ghia, Andre Goy, Gilles A. Salles, Steve Abella, Betsy Philip, Bess Sorenson, Nina D. Wagner-Johnston., ASH Annual Meeting Abstracts, 1/1/2015
• Insights into the Management of Adverse Events in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Experience from the Phase 3...
  Asher Chanan-Khan, Paula Cramer, Fatih Demirkan, Graeme Fraser, Rodrigo Santucci Silva, Halyna Pylypenko, Sebastian Grosicki, Ann Janssens, Aleksander Pristupa, Andre ..., ASH Annual Meeting Abstracts, 1/1/2015
• Improvement of Quality of Response with Ibrutinib Plus Bendamustine/Rituximab Vs Placebo Plus Bendamustine/Rituximab for Previously Treated Chronic Lymphocytic Leukemi...
  Paula Cramer, Asher Chanan-Khan, Graeme Fraser, Fatih Demirkan, Rodrigo Santucci Silva, Halyna Pylypenko, Sebastian Grosicki, Ann Janssens, Andre Goy, Jiri Mayer, Mari..., ASH Annual Meeting Abstracts, 1/1/2015
• A phase 1 dose-escalation study of the oral selective inhibitor of nuclear export (SINE) KPT-330 (selinexor) in patients (pts) with heavily pretreated non-Hodgkin lymp...
  Martin Gutierrez, Andre Goy, John C. Byrd, Joseph M. Flynn, Morten Sorensen, Peter Brown, Nashat Y. Gabrail, Michael Savona, Ian Flinn, Rachid C. Baz, Bijal D. Shah, R..., J Clin Oncol, 1/1/2014
• Patient-reported outcomes data from a phase 2 study of idelalisib in patients with refractory indolent B-cell non-Hodgkin lymphoma (iNHL).
  Nina D. Wagner-Johnston, Ajay K. Gopal, Brad S. Kahl, Sven De Vos, Stephen J. Schuster, Wojciech Jurczak, Ian Flinn, Christopher Flowers, Peter Martin, Andreas Viardot..., J Clin Oncol, 1/1/2014
• Welcome Peripheral T-cell lymphomas (PTCL) in the modern era: Prognosis and impact of therapy in a large U.S. multicenter cohort.
  Jeremy S. Abramson, Tatyana Feldman, Aimee Kroll, Lori S. Muffly, Eric S. Winer, Christopher Flowers, Frederick Lansigan, Chadi Nabhan, Rajneesh Nath, Jorge J. Castill..., J Clin Oncol, 1/1/2014
• Post-treatment PET scan is highly predictive of outcome (PFS and OS) in MCL pts treated with R-Hyper-CVAD in the frontline setting regardless of MIPI score.
  Anthony R. Mato, Ewelina Protomastro, Tania Zielonka, Tatyana Feldman, Harry Agress, Mary Timberg, Gabriella Gadaleta, Pritish Bhattacharyya, Alexandria Campaiola, Jak..., J Clin Oncol, 1/1/2014
• Retrospective analysis of treatment patterns and outcomes with subcutaneous (SQ) bortezomib (BTZ) in patients (pts) with relapsed mantle cell lymphoma (MCL).
  Vijayveer Bonthapally, Marie-Helene Lafeuille, Jonathan Fortier, Mei Sheng Duh, Yvette Ng, Helgi Van De Velde, Liviu Niculescu, Esprit Ma, Andre Goy, J Clin Oncol, 1/1/2014
• Phase IIa study of single-agent MOR208 in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL).
  Wojciech Jurczak, Pier Luigi Zinzani, Andre Goy, Mariano Provencio, Zsolt Nagy, Tadeusz Robak, Kami J. Maddocks, Christian Buske, Roman Korolkiewicz, Mark Winderlich, ..., ASCO, 1/1/2014
• Prevalence of clinically meaningful prognostic variability in cancer: An analysis using a new taxonomy system
  Andrew Pecora, Eric V Schultz, Kelly Choi, Augie Smith, Brian LaRock, Dhakshila Paramanathan, William T. DeRosa, Andre Goy, Edward J. Licitra, David Samuel DiCapua Sie..., ASCO, 1/1/2014
• Join now to see all

Lectures

• How I Think, How I Treat - BTK Inhibitors as a Clinical Strategy in CLL, MCL, and Beyond: Therapeutic Selection, Sequencing, and Next Steps 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Emerging Paradigms to Address Unmet Needs in Relapsed/Refractory DLBCL 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Safety and Efficacy Data for Combined Checkpoint Inhibition with Ipilimumab (Ipi) and Nivolumab (Nivo) As Consolidation Following Autologous Stem Cell Transplantation ... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Elevated IL-1Ra Levels in the Stem Cell Product Is Associated with the Development of Engraftment Syndrome Following Autologous Stem Cell Transplantation for the Treat... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World ExperienceClinically Re... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Exploring the Present and Future of BTK Inhibition in B-Cell Malignancies: Expert Insights on Practical Implications for Patient Management 
  60th American Society of Hematology Annual Meeting - 11/30/2018
• Updates on Lymphoma and Treatment Options 
  Hackensack, NJ - 1/1/2016
• MCL: Changing Paradigm? 
  New York - 1/1/2016
• Relapsed/Refractory Status: Old/New Agents- Lenalidomide 
  Bologna, Italy - 1/1/2014
• Targeted Therapies in Early, Mid, and Late Development- Building on R-CHOP by Tackling the Lymphoma Microenvironment 
  1/1/2014
• Celgene: IMiDs in Mantle Cell Lymphoma 
  Munich, Germany - 1/1/2013
• Inotuzumab Ozogamicin 
  Bologna, Italy - 1/1/2013
• New Drugs in Hematology 
  Bologna, Italy - 1/1/2013
• Novel Approaches in Mantle Cell Lymphoma 
  Switzerland - 1/1/2013
• Advanced-Stage DLBCL 
  New York, NY - 1/1/2013
• Stem Cell Transplantation in Indolent Lymphoma 
  New York, NY - 1/1/2013
• IMIDs in Lymphoma 
  New York, NY - 1/1/2013
• Novel Agents for Follicular and Mantle Cell Lymphomas 
  New York, NY - 1/1/2013
• Novel Agents for Follicular and Mantle-Cell Lymphomas 
  New York, NY - 1/1/2013
• Debate: “What is the best upfront treatment for mantle-cell lymphoma in a 60 year old patient? Chemoimmunotherapy followed by maintenance” 
  New York, NY - 1/1/2013
• Other Novel Targeted Agents of Clinical Interest for NHL and/or CLL and Their Potential Importance 
  Washington, D.C. - 1/1/2013
• Updates in Relapsed Mantle Cell Lymphoma 
  NJ - 1/1/2013
• New Treatment Option in Previously Treated Mantle Cell Lymphoma 
  NJ - 1/1/2013
• Therapeutic options on mantle cell lymphoma on first line and at relapse 
  Cancun, Mexico - 1/1/2012
• Debate: Should an asymptomatic patient with low tumor burden Mantle Cell Lymphoma be observed or receive immediate treatment? Immediate treatment is the best option. 
  New York, NY - 1/1/2012
• Join now to see all

Other

• Complications of Monoclonal Antibodies in Hematological Malignancies 
  New Book Infectious Diseases in Immunocompromised Host
  1/1/2009
• Diagnosis and Management of Other Lymphoproliferative Disorders. 
  Goy A H, Amin HM, Cabanillas F, Medeiros LJ, Non-Hodgkin’s Lymphomas
  1/1/2004